Anja Holtz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anja Holtz has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Austin Chen
Contineum Therapeutics, 3565 General Atomics Court, Suite 200, San Diego, California 92121, United States
41 shared publications - Brian J. Francica
Tempest Therapeutics, Brisbane, California
41 shared publications - Chan C. Whiting
10Tempest Therapeutics, Brisbane, California
41 shared publications - David Freund
Tempest Therapeutics, Brisbane, California
41 shared publications - David Powell
Chinook Therapeutics, Inc., Seattle, Washington
41 shared publications - Dingzhi Wang
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina. 1
41 shared publications
Latest Publications
- 30 June 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (7) , 1375-1391
Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction
Tauopathies encompass a range of neurodegenerative disorders, such as Alzheimer’s disease (AD) and frontotemporal lobar degeneration with tau inclusions (FTLD-tau), for which there are currently no successful treatments. Here, we show impaired glycogen metabolism in the brain of a tauopathy Drosophila melanogaster model and people with AD, indicating a link between tauopathies and glycogen metabolism. We demonstrate that the breakdown of neuronal glycogen ameliorates the tauopathy phenotypes in flies and induced pluripotent stem cell (iPSC)-derived neurons from people with FTLD-tau. Glycogen breakdown redirects glucose flux to the pentose phosphate pathway and alleviates oxidative stress. Our findings uncover a critical role for the neuroprotective effects of dietary restriction (DR) by increasing glycogen breakdown. Mechanistically, we show a potential interaction between tau protein and glycogen, suggesting a vicious cycle in which tau binding promotes glycogen accumulation in neurons, which in turn exacerbates tau accumulation which further disrupts cellular homeostasis. Our studies identify impaired glycogen metabolism as a key hallmark for tauopathies and offer a promising therapeutic target in tauopathy and other neurodegenerative diseases.
- 30 June 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (7) , 1375-1391
Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction
Tauopathies encompass a range of neurodegenerative disorders, such as Alzheimer’s disease (AD) and frontotemporal lobar degeneration with tau inclusions (FTLD-tau), for which there are currently no successful treatments. Here, we show impaired glycogen metabolism in the brain of a tauopathy Drosophila melanogaster model and people with AD, indicating a link between tauopathies and glycogen metabolism. We demonstrate that the breakdown of neuronal glycogen ameliorates the tauopathy phenotypes in flies and induced pluripotent stem cell (iPSC)-derived neurons from people with FTLD-tau. Glycogen breakdown redirects glucose flux to the pentose phosphate pathway and alleviates oxidative stress. Our findings uncover a critical role for the neuroprotective effects of dietary restriction (DR) by increasing glycogen breakdown. Mechanistically, we show a potential interaction between tau protein and glycogen, suggesting a vicious cycle in which tau binding promotes glycogen accumulation in neurons, which in turn exacerbates tau accumulation which further disrupts cellular homeostasis. Our studies identify impaired glycogen metabolism as a key hallmark for tauopathies and offer a promising therapeutic target in tauopathy and other neurodegenerative diseases.
- Open Access
- 8 November 2023
- Published by Springer Nature in Research Square
Neuronal Glycogen Breakdown Mitigates Tauopathy via Pentose Phosphate Pathway-Mediated Oxidative Stress Reduction
Tauopathies encompass a range of neurodegenerative disorders, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). Unfortunately, current treatment approaches for tauopathies have yielded limited success, underscoring the pressing need for novel therapeutic strategies. We observed distinct signatures of impaired glycogen metabolism in the Drosophila brain of the tauopathy model and the brain of AD patients, indicating a link between tauopathies and glycogen metabolism. We demonstrate that the breakdown of neuronal glycogen by activating glycogen phosphorylase (GlyP) ameliorates the tauopathy phenotypes in flies and induced pluripotent stem cell (iPSC) derived neurons from FTD patients. We observed that glycogen breakdown redirects the glucose flux to the pentose phosphate pathway to alleviate oxidative stress. Our findings uncover a critical role for increased GlyP activity in mediating the neuroprotection benefit of dietary restriction (DR) through the cAMP-mediated protein kinase A (PKA) activation. Our studies identify impaired glycogen metabolism as a key hallmark for tauopathies and offer a promising therapeutic target in tauopathy treatment.
- 8 November 2023
- Published by Springer Nature in Research Square
Open AccessNeuronal Glycogen Breakdown Mitigates Tauopathy via Pentose Phosphate Pathway-Mediated Oxidative Stress Reduction
Tauopathies encompass a range of neurodegenerative disorders, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). Unfortunately, current treatment approaches for tauopathies have yielded limited success, underscoring the pressing need for novel therapeutic strategies. We observed distinct signatures of impaired glycogen metabolism in the Drosophila brain of the tauopathy model and the brain of AD patients, indicating a link between tauopathies and glycogen metabolism. We demonstrate that the breakdown of neuronal glycogen by activating glycogen phosphorylase (GlyP) ameliorates the tauopathy phenotypes in flies and induced pluripotent stem cell (iPSC) derived neurons from FTD patients. We observed that glycogen breakdown redirects the glucose flux to the pentose phosphate pathway to alleviate oxidative stress. Our findings uncover a critical role for increased GlyP activity in mediating the neuroprotection benefit of dietary restriction (DR) through the cAMP-mediated protein kinase A (PKA) activation. Our studies identify impaired glycogen metabolism as a key hallmark for tauopathies and offer a promising therapeutic target in tauopathy treatment.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 effectively increases survival and modulates the TME in APCmin/+ mice. A, Tumor counts in the small intestine of APCmin/+ mice. Mice were treated starting at 13 weeks of age for 3 weeks with TPST-1495 (100 mg/kg twice a day, orally), E7046 (150 mg/kg every day, orally), PF04418948 (100 mg/kg every day, orally), or Celecoxib (60 mg/kg every day, orally). Results are representative of multiple experiments with 7–10 mice. B, Kaplan–Meier curve of survival of APCmin/+ mice and log-rank Mantel–Cox P values of listed comparisons. Mice were ages to 13 weeks, then treated with as in A or with the combination of E7046 and PF04418948 at monotherapy doses, for 6 weeks. Survival was monitored longitudinally and mice were sacrificed as they became moribund. Results are representative of two similar experiments with 8 mice per group. C, IHC of tumor or hyperplasia excised from small intestines of mice from experiment in A. Quantification displays values from one tumor in each biological replicate. TPST-1495 every day and twice a day groups are concatenated because of limited tumor tissue in these groups. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. BID, twice a day; QD, every day.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 effectively increases survival and modulates the TME in APCmin/+ mice. A, Tumor counts in the small intestine of APCmin/+ mice. Mice were treated starting at 13 weeks of age for 3 weeks with TPST-1495 (100 mg/kg twice a day, orally), E7046 (150 mg/kg every day, orally), PF04418948 (100 mg/kg every day, orally), or Celecoxib (60 mg/kg every day, orally). Results are representative of multiple experiments with 7–10 mice. B, Kaplan–Meier curve of survival of APCmin/+ mice and log-rank Mantel–Cox P values of listed comparisons. Mice were ages to 13 weeks, then treated with as in A or with the combination of E7046 and PF04418948 at monotherapy doses, for 6 weeks. Survival was monitored longitudinally and mice were sacrificed as they became moribund. Results are representative of two similar experiments with 8 mice per group. C, IHC of tumor or hyperplasia excised from small intestines of mice from experiment in A. Quantification displays values from one tumor in each biological replicate. TPST-1495 every day and twice a day groups are concatenated because of limited tumor tissue in these groups. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05. BID, twice a day; QD, every day.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of CT26 tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human whole blood treated with TPST-1495 (A) or E7046 (B) in the presence of 10 nmol/L or 500 nmol/L PGE2. Graphs show one representative donor of 3 donors tested. C–E, IFNγ concentration in supernatants of PGE2 blockade assay performed on magnetically enriched T cells from human PBMC. Cells were treated with various concentrations of EP receptor inhibitors TPST-1495 (C), E7046 (D), or PF04418948 (E), followed by concentrations of PGE2 and CEF peptides as shown in C and D. Cytokine levels in supernatants were determined by bead-based cytokine array analysis. Graphs show data with N = 4 technical replicates from one of four independent experiments. Two different healthy donors were used across these experiments. F, Percent IFNγ production rescue, as normalized to the control (DMSO), from PGE2 Blockade assay supernatants. Magnetically enriched T Cells from human PBMC were treated with increasing amounts of EP1 (Ono-8130) and EP3 (L-798106) inhibitors and subjected to 333 nmol/L PGE2 before stimulation with CEF peptides. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. G, Percent IFNγ production rescue, as normalized to control with 0 nmol/L PGE2 and 0 nmol/L TPST-1495. Cells obtained as in C–F were treated with increasing TPST-1495 in the presence or absence of 10 mmol/L EP1 inhibitor and 10 mmol/L EP3 inhibitor. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human whole blood treated with TPST-1495 (A) or E7046 (B) in the presence of 10 nmol/L or 500 nmol/L PGE2. Graphs show one representative donor of 3 donors tested. C–E, IFNγ concentration in supernatants of PGE2 blockade assay performed on magnetically enriched T cells from human PBMC. Cells were treated with various concentrations of EP receptor inhibitors TPST-1495 (C), E7046 (D), or PF04418948 (E), followed by concentrations of PGE2 and CEF peptides as shown in C and D. Cytokine levels in supernatants were determined by bead-based cytokine array analysis. Graphs show data with N = 4 technical replicates from one of four independent experiments. Two different healthy donors were used across these experiments. F, Percent IFNγ production rescue, as normalized to the control (DMSO), from PGE2 Blockade assay supernatants. Magnetically enriched T Cells from human PBMC were treated with increasing amounts of EP1 (Ono-8130) and EP3 (L-798106) inhibitors and subjected to 333 nmol/L PGE2 before stimulation with CEF peptides. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. G, Percent IFNγ production rescue, as normalized to control with 0 nmol/L PGE2 and 0 nmol/L TPST-1495. Cells obtained as in C–F were treated with increasing TPST-1495 in the presence or absence of 10 mmol/L EP1 inhibitor and 10 mmol/L EP3 inhibitor. Each datapoint represents the average percent recovery from one experiment, with four total experiments shown. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Antibodies used for IHC of APCmin/+ tumors
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 7 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Effective antagonism of PGE2 signaling modulates significant transcriptional shifts in the TME. A, Volcano plots of selected genes. Blue coloration represents significantly (Padj < 0.05) downregulated genes while red correlation represents significantly upregulated genes. Genes in gray did not meet the significance cutoff. B, Heat map depicting significantly upregulated gene sets from GSEA performed on RNA sequencing analysis above and representative GSEA plot from IFNγ signature. All results represent data from one experiment with 4 animals per group. *** indicates FDR < 0.25 for that gene set compared with vehicle-treated animals.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 7 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Effective antagonism of PGE2 signaling modulates significant transcriptional shifts in the TME. A, Volcano plots of selected genes. Blue coloration represents significantly (Padj < 0.05) downregulated genes while red correlation represents significantly upregulated genes. Genes in gray did not meet the significance cutoff. B, Heat map depicting significantly upregulated gene sets from GSEA performed on RNA sequencing analysis above and representative GSEA plot from IFNγ signature. All results represent data from one experiment with 4 animals per group. *** indicates FDR < 0.25 for that gene set compared with vehicle-treated animals.
- Open Access
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Expression profiles of PGE2 receptors EP2 and EP4 across diverse human malignancies. A, Expression of EP2 (PTGER2) and EP4 (PTGER4) across cancer indications indicated in the figure using RNA sequencing data from TCGA Pan Cancer dataset obtained through cBIO Portal. Selected cancer types are labeled with TCGA abbreviations. B, Heat map of EP2 and EP4 expression across the selected malignancies, with definition of TCGA tumor type abbreviations defined. C, Heat map analysis of percent positive samples for designated prostaglandin pathway genes, including PTGER4, PTGS2, PTGES2, and PTGES from the Protein Atlas database.
- 8 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
Expression profiles of PGE2 receptors EP2 and EP4 across diverse human malignancies. A, Expression of EP2 (PTGER2) and EP4 (PTGER4) across cancer indications indicated in the figure using RNA sequencing data from TCGA Pan Cancer dataset obtained through cBIO Portal. Selected cancer types are labeled with TCGA abbreviations. B, Heat map of EP2 and EP4 expression across the selected malignancies, with definition of TCGA tumor type abbreviations defined. C, Heat map analysis of percent positive samples for designated prostaglandin pathway genes, including PTGER4, PTGS2, PTGES2, and PTGES from the Protein Atlas database.